Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-09 · 44 (9) · 1960-1974
DOI: 10.1161/atvbaha.124.321008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-09. Verfasst von Haotian Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Stony Brook School of Medicine, NY (H. Zhang, N.K., K.M., X.Y., H. Zhan). Hauptthemen laut MEDLINE: Janus Kinase 2, Receptors, Thrombopoietin, Myeloproliferative Disorders, Mutation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BLRD VA, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) and clonal hematopoiesis of indeterminate potential face a significantly elevated risk of cardiovascular diseases. Endothelial cells carrying the JAK2V617F mutation have been detected in many patients with MPN. In this study, we investigated the molecular basis for the high incidence of cardiovascular complications in patients with MPN. METHODS: We investigated the impact of endothelial JAK2V617F mutation on cardiovascular disease development using both transgenic murine models and MPN patient–derived induced pluripotent stem cell lines. RESULTS: Our investigations revealed that JAK2V617F mutant endothelial cells promote cardiovascular diseases under stress, which is associated with endothelial-to-mesenchymal transition and endothelial dysfunction. Importantly, we discovered that inhibiting the endothelial TPO (thrombopoietin) receptor MPL (myeloproliferative leukemia virus oncogene) suppressed JAK2V617F-induced endothelial-to-mesenchymal transition and prevented cardiovascular dysfunction caused by mutant endothelial cells. Notably, the endothelial MPL receptor is not essential for the normal physiological regulation of blood cell counts and cardiac function. CONCLUSIONS: JAK2V617F mutant endothelial cells play a critical role in the development of cardiovascular diseases in JAK2V617F-positive MPNs, and endothelial MPL could be a promising therapeutic target for preventing or ameliorating cardiovascular complications in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Stony Brook School of Medicine, NY (H. Zhang, N.K., K.M., X.Y., H. Zhan).
- The Graduate Program in Molecular and Cellular Biology (H. Zhang), Stony Brook University, NY.
- Department of Molecular and Cellular Pharmacology (S.L.), Stony Brook University, NY.
- Division of Rheumatology, Peking Union Medical College Hospital, Beijing, China (X.Y.).
- Cardiac Imaging, The Heart Center, Saint Francis Hospital, Roslyn, NY (H. Zheng).
- Medical Service, Northport VA Medical Center, NY (H. Zhan).
ORCID-Profile: Haotian Zhang, Sandy Lee, Haoyi Zheng, Huichun Zhan
Förderung
- BLRD VA
- NCI NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Zhang, H., Kafeiti, N., Masarik, K., Lee, S., Yang, X., Zheng, H., & Zhan, H. (2024). Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(9), 1960-1974. https://doi.org/10.1161/atvbaha.124.321008
Vancouver
Zhang H, Kafeiti N, Masarik K, Lee S, Yang X, Zheng H, et al. Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(9):1960-1974. doi:10.1161/atvbaha.124.321008
BibTeX
@article{Zhang2024,
author = {Zhang, Haotian and Kafeiti, Nicholas and Masarik, Kyla and Lee, Sandy and Yang, Xiaoxi and Zheng, Haoyi and Zhan, Huichun},
title = {Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
volume = {44},
number = {9},
pages = {1960--1974},
doi = {10.1161/atvbaha.124.321008}
}
EUVIMED